Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dai FukumuraEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USAJonas KloepperDepartment of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne (CHUV-UNIL), Lausanne, Vaud, SwitzerlandZohreh AmoozgarEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USADan G. DudaEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USARakesh K. JainEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
2018en
ABI
Аннотация
Аннотация мавжуд эмас.
Идентификаторлар
Иқтибослар ва манбалар
3 та иқтибос0 та фойдаланилган манба